Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia

Metabolism: Clinical and Experimental

Volumn 55, Issue 1, 2006, Pages 78-83

  Szoke, Ervin ^a   Gosmanov, Niyaz R ^a   Sinkin, Jeremy C ^a   Nihalani, Amit ^a   Fender, Anne B ^a   Cryer, Philip E ^b   Meyer, Christian ^c   Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C PEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; INSULIN;

ADULT; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; FEMALE; GLUCAGON RELEASE; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOTHESIS; INSULIN INFUSION; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; EPINEPHRINE; FEMALE; GLUCOSE; GLYBURIDE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE; SULFONYLUREA COMPOUNDS;

EID: 28444497052     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.07.009     Document Type: Article

References (42)

1. J. Gerich Oral hypoglycemic agents N Engl J Med 321 1989 1231 1245
2. P.E. Cryer Diverse causes of hypoglycemia-associated autonomic failure in diabetes N Engl J Med 350 2004 2272 2279
3. A.J. Krentz, R.E. Ferner, and C.J. Bailey Comparative tolerability profiles of oral antidiabetic agents Drug Saf 11 1994 223 241
4. R. DeFronzo Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 1999 281 303
5. S. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: scientific review JAMA 287 2002 360 372
6. A. Holstein, A. Plaschke, and E.-H. Egberts Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev 17 2001 467 473
7. U. Lindblad, and A. Melander Sulphonylurea dose-response relationships: relation to clinical practice Diabetes Obes Metab 2 2000 25 31
8. B. Hellman, J. Sehlin, and I.B. Taljedal Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets Acta Endocrinol (Copenh) 105 1984 385 390
9. W. Kramer, G. Muller, and K. Geisen Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells Horm Metab Res 28 1996 464 468
10. G. Muller, D. Hartz, J. Punter, R. Okonomopulos, and W. Kramer Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics Biochim Biophys Acta 1191 1994 267 277
11. + channels in rat pancreatic A-cells Pflugers Arch 438 1999 428 436
12. + (KATP) conductance in rat pancreatic A-cells J Physiol 527 Pt 1 2000 109 120
13. + channels in alpha-TC glucagonoma and beta-TC insulinoma cells Diabetes 42 1993 1760 1772
14. + channels in clonal pancreatic alpha cells. Evidence for two high affinity sulfonylurea receptors J Biol Chem 268 1993 15221 15228
15. + channels J Physiol 528 Pt 3 2000 509 520
16. E. Samols, J.M. Tyler, and P. Mialhe Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas Lancet 1 1969 174 176
17. K. Takahashi, K. Yamatani, M. Hara, and H. Sasaki Gliclazide directly suppresses arginine-induced glucagon secretion Diabetes Res Clin Pract 24 1994 143 151
18. K. Cejvan, D.H. Coy, J.J. Holst, E. Cerasi, and S. Efendic Gliclazide directly inhibits arginine-induced glucagon release Diabetes 51 Suppl 3 2002 S381 S384
19. C.G. Ostenson, A. Nylen, V. Grill, M. Gutniak, and S. Efendic Sulfonylurea-induced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct, non-paracrine effect Diabetologia 29 1986 861 867
20. Y. Sako, T. Wasada, F. Umeda, and H. Ibayashi Effect of glibenclamide on pancreatic hormone release from isolated perifused islets of normal and cysteamine-treated rats Metabolism 35 1986 944 949
21. H. Hirose, H. Maruyama, Y. Seto, K. Ito, T. Fujita, and K. Dan Effects of d-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide Pharmacology 50 1995 175 181
22. G.M. Grodsky, G.H. Epstein, R. Fanska, and J.H. Karam Pancreatic action of the sulfonylureas Fed Proc 36 1977 2714 2719
23. F. Gregorio, F. Ambrosi, S. Cristallini, P. Filipponi, and F. Santeusanio Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations Acta Diabetol 33 1996 25 29
24. E. Tsalikian, T. Dunphy, N. Bohannon, M. Lorenzi, J. Gerich, and P. Forsham The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal Diabetes 26 1977 314 321
25. S.R. Peacey, A. Rostami-Hodjegan, E. George, G.T. Tucker, and S.R. Heller The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal human beings J Clin Endocrinol Metab 82 1997 1458 1461
26. E.W. ter Braak, A.M. Appelman, I. van der Tweel, D.W. Erkelens, and T.W. van Haeften The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia Diabetes Care 25 2002 107 112
27. L. Landstedt-Hallin, U. Adamson, and P.E. Lins Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes J Clin Endocrinol Metab 84 1999 3140 3145
28. P. DeFeo, G. Perriello, M. Ventura, F. Calcinaro, G. Basta, and C. Lolli Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon Diabetologia 29 1986 475 480
29. M. Mokan, and J. Gerich A simple insulin infusion algorithm for establishing and maintaining overnight near-normoglycemia in type I and type II diabetes J Clin Endocrinol Metab 74 1992 943 945
30. R. DeFronzo, J. Tobin, and R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 E214 E223
31. N. Abumrad, D. Rabin, M. Diamond, and W. Lacy Use of a heated superficial hand vein as an alternate site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man Metabolism 30 1981 936 940
32. S.D. Shah, W.E. Clutter, and P.E. Cryer External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma norepinephrine and epinephrine J Lab Clin Med 106 1985 624 629
33. C. Meyer, J. Dostou, and J. Gerich Role of the human kidney in glucose counterregulation Diabetes 48 1999 943 948
34. R. Eaton, R. Allen, D. Schade, K. Erickson, and J. Standefer Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior J Clin Endocrinol Metab 51 1980 520 528
35. K.S. Polonsky, J. Licinio-Paixao, B.D. Given, W. Pugh, P. Rue, and J. Galloway Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients J Clin Invest 77 1986 98 105
36. E. Van Cauter, F. Mestrez, J. Sturis, and K.S. Polonsky Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance Diabetes 41 1992 368 377
37. R. Hovorka, and R.H. Jones How to measure insulin secretion Diabetes Metab Rev 10 1994 91 117
38. E. Bingham, D. Hopkins, A. Pernet, H. Reid, I.A. Macdonald, and S.A. Amiel The effects of KATP channel modulators on counterregulatory responses and cognitive function during acute controlled hypoglycaemia in healthy men: a pilot study Diabet Med 20 2003 231 237
39. T. Kadowaki Insights into insulin resistance and type 2 diabetes from knockout mouse models J Clin Invest 106 2000 459 465
40. F. Gregorio, F. Ambrosi, S. Cristallini, M. Pedetti, P. Filipponi, and F. Santeusanio Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function Diabetes Res Clin Pract 18 1992 197 206
41. H. Langtry, and J. Balfour Glimepiride. A review of its use in the management of type 2 diabetes mellitus Drugs 55 1998 563 584
42. K.H. Lehr, and P. Damm Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization J Chromatogr 526 1990 497 505